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ORIGINAL INVESTIGATION

Association of TyG index and TG/HDL‑C
ratio with arterial stiffness progression
in a non‑normotensive population
Zhiyuan Wu1,3†, Di Zhou1†, Yue Liu1, Zhiwei Li1, Jinqi Wang1, Ze Han1, Xinlei Miao1, Xiangtong Liu1, Xia Li2,
Wei Wang3, Xiuhua Guo1,2* and Lixin Tao1,2*

Abstract
Background: Cross-sectional studies have reported that insulin resistance (IR) is associated with arterial stiffness.
However, the relationship between IR and arterial stiffness progression remains unclear. This study aims to evaluate
the association of triglyceride glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C)
ratio with arterial stiffness progression in a non-normotensive population.
Methods: A total of 1895 prehypertensive (systolic pressure 120–139 mmHg or diastolic pressure 80–90 mmHg) or
hypertensive (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg or using antihypertensive medication)
participants were enrolled in 2013 and 2014, and followed until December 31, 2019. Arterial stiffness progression
was measured by brachial-ankle pulse wave velocity (baPWV) change (absolute difference between baseline and
last follow-up), baPWV change rate (change divided by following years), and baPWV slope (regression slope between
examination year and baPWV).
Results: During a median follow-up of 4.71 years, we observed an increasing trend of baPWV in the population.
There were linear and positive associations of the TyG index and TG/HDL-C ratio with the three baPWV parameters.
The difference (95% CI) in baPWV change (cm/s) comparing participants in the highest quartile versus the lowest of
TyG index and TG/HDL-C ratio were 129.5 (58.7–200.0) and 133.4 (52.0–214.9), respectively. Similarly, the evaluated
baPWV change rates (cm/s/year) were 37.6 (15.3–60.0) and 43.5 (17.8–69.2), while the slopes of baPWV were 30.6
(9.3–51.8) and 33.5 (9.0–58.0). The observed association was stronger in the hypertensive population.
Conclusion: Our study indicates that the TyG index and TG/HDL-C ratio are significantly associated with arterial stiffness progression in hypertensive population, not in prehypertensive population.
Keywords: Insulin resistance, Arterial stiffness, Hypertension, Triglyceride glucose index, TG/HDL-C ratio, Cohort study
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Background
Hypertension has caused a heavy economic burden
worldwide, becoming a challenging public health issue.
In 2010, 31.1% of adults around the world were reported
to have hypertension [1]. Among Chinese adults aged
35–75 years, nearly half are diagnosed with hypertension,
the incidence is still steadily increasing, and the onset age
is becoming younger [2]. Among hypertensive patients,
arterial stiffness is a common vascular complication and
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is also an independent risk factor and predictor of other
cardiovascular and cerebrovascular diseases [3, 4], such
as coronary heart disease (CHD) and stroke. Therefore, it
is of great importance to focus on the progression of arterial stiffness in the hypertensive population and identify
the early related factors of arterial stiffness [5–7].
Disorders of glucose and lipid metabolism are a common pathophysiological feature accompanying patients
with hypertension, while insulin resistance (IR) extensively participates in this biological process [8]. The
hyperinsulinaemic-euglycaemic clamp is the gold standard for evaluating the status of IR [9]. However, this
assessment process is expensive and complex and is not
ideal for routine clinical monitoring. Recently, some
novel and simple indicators have been reported to be
reliable surrogate indexes of IR, such as the triglycerideglucose (TyG) index and the triglyceride to high-density
lipoprotein cholesterol (TG/HDL-C) ratio. Compared
with the hyperinsulinaemic-euglycaemic clamp, the TyG
index has a high sensitivity of 96.5% and a specificity of
85.0% for the diagnosis of IR [10], which has also been
reported to be associated with diabetes in Chinese population [11]. Many studies have found that these surrogate
indexes are independent risk factors for some cerebrocardiovascular diseases [12–14]. Moreover, IR-related
indexes are associated with arterial stiffness [15–19].
However, these studies are all based on general populations. Recently, Li et al. [20] found that the TyG index
is positively associated with brachial-ankle pulse wave
velocity (baPWV) in hypertensive patients. However, this
study is a cross-sectional study without follow-up. Moreover, the association between the TG/HDL-C ratio and
arterial stiffness remains unreported.
Therefore, we aimed to comprehensively investigate the
association between the TyG index and TG/HDL-C ratio
with arterial stiffness progression in prehypertensive and
hypertensive populations based on a prospective cohort
study.

Methods
Study design and participants

The Beijing health management cohort (BHMC) is an
open cohort study established in 2008 in Beijing, China,
with new individuals recruited annually. The BHMC
study was conducted based on health examination populations from the Beijing Xiaotangshan Examination
Center and Beijing Physical Examination Center. BHMC
was designed to investigate the risk factors and biomarkers for metabolism-related diseases, and the recruited
individuals were asked to take an annual health examination, including physical examination (anthropometry
variables, blood pressures), face-to-face questionnaire
survey (demographic variables, lifestyles, diseases
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history, medication history) and biochemical examination. Details of the study design have been described
previously [21]. The arterial stiffness-related variables,
such as baPWV and ankle brachial index (ABI), were
available from 2013. Therefore, individuals taking health
examinations in 2013 and 2014 were recruited in this
current study as a baseline. Of 22,746 participants who
underwent health examination at baseline, 2327 were
confirmed to have prehypertension or hypertension. To
minimize the possible influence of medication on glucose and lipid levels, 42 participants using antidiabetic
agents and 52 participants using lipid-lowering agents
were excluded. In addition, we excluded 101 participants
with CHD, stroke or other cerebrocardiovascular diseases. Nineteen participants with any malignancy were
excluded. Twenty-three participants from whom we were
unable to collect the required data at baseline and 188
participants lost to follow-up, defined as without health
examination records until 2019, were further excluded
from the analyses. Finally, this study was restricted to a
subset of 1895 participants with complete data, which
were used in the final analyses, as shown in Fig. 1. Most
of the participants (98%) enrolled in this current study
came from a work unit in Beijing, and there were a total
of 407 units included.
This study was in accordance with the principles of
the Declaration of Helsinki and approved by the Ethics
Committee of Capital Medical University (grant number:
2020SY031). All participants provided written informed
consent before taking part in this study.
Data collection and definitions

The demographic characteristics, lifestyle, and medication-related information were collected via a standard questionnaire by our trained staff, including age,
sex, occupation, smoking status, drinking status, regular physical activity, diagnosis history of diseases and
medication information. Occupation in this current
study was classified into ‘manager’, ‘technician or professional’, ‘worker’ and ‘retired’. Smoking status was defined
as ‘current smoker’, ‘former smoker’ and ‘never smoked’.
Drinking status was defined as ‘current drinking’ and ‘no
current drinking’. Physical activity was defined as having moderate or intense exercise ‘ ≥ 80 min per weak’
and ‘ < 80 min per week or none’. The physical and biochemical examination data were acquired from the electronic medical record system. Body mass index (BMI)
was calculated as weight (in kilograms)/height^2 (in
metres squared). Systolic blood pressure (SBP) and
diastolic blood pressure (DBP) were presented as the
average of two measurements on the right arm using
a sphygmomanometer after resting for at least 10 min.
Based on the JNC-7 criteria [22], hypertension status
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22,746 participants (aged≥20) underwent
health examination in 2013 and 2014
20,419 participants were excluded with normal
blood pressure
2,327 participants eligible for inclusion as baseline
Excluded:
19 participants with any malignancy
101 participants with CHD, stroke or other
cerebro-cardiovascular diseases
42 participants with antidiabetic and 59 with lipidlowering medicine
23 participants unable to collect the required data
2,083 followed from 2013-2014 until
December 31, 2019
188 participants were lost to follow up
1,895 enrolled in final analysis
Fig. 1 Flow chart of the study population

was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg
or use of any antihypertensive medication. Prehypertension status was defined as SBP of 120–139 mmHg
or DBP of 80–89 mmHg. The mean arterial pressure
(MAP) was calculated as 1/3*SBP + 2/3*DBP. A higher
vascular stiffness increases pulse pressure (PP), while PP
could increase SBP and decrease DBP to a small extent.
Therefore, the MAP level was adjusted in the following
analyses.
Blood samples were stored and measured in the central
laboratory of Beijing Xiaotangshan Examination Center
or Beijing Physical Examination Center using the Olympus Automatic Biochemical Analyser (Hitachi 747; Tokyo,
Japan). Serum total cholesterol (TC), triglyceride (TG), highdensity lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C) were measured with the
enzymatic colour metric method. The estimated glomerular
filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2009)
serum creatinine equation [23]. Fasting blood glucose (FBG)
was defined as the glucose concentrations before breakfast
after overnight fasting (no food, except drinking water, for
at least 8–10 h), while two-hour postprandial blood glucose (PBG) was measured 2 h after the beginning of fixed

meals through finger blood tests. Diabetes was defined as
FBG ≥ 7.0 mmol/L, PBG ≥ 11.1 mmol/L, glycated haemoglobin (HbA1c) ≥ 6.5% or the use of any glucose-lowering
medication according to the American Diabetes Association
[24]. According to the Guidelines on Prevention and Treatment of Dyslipidaemia for Chinese Adults [25], dyslipidaemia was defined as TG ≥ 2.3 mmol/L, TC ≥ 6.2 mmol/L,
LDL-C ≥ 4.1 mmol/L, HDL-C < 1.0 mmol/L, or any lipidlowering medication. The TyG index was denoted as ln[TG
(mm/L)*fasting glucose (mm/L)/2]. The TG/HDL-C ratio
was calculated as TG (mm/L) divided by HDL-C (mm/L).
Assessment of baPWV

baPWV is a simple, noninvasive, automatic and widely
used method in clinical practice and large populationbased studies. The baPWV was measured with an Omron
Colin BP-203RPE III device (Omron Health Care, Kyoto,
Japan). After more than 5 min of rest in the supine position, 4 cuffs were wrapped around the bilateral brachia
and ankles and then connected to a plethysmographic
sensor and oscillometric pressure sensor. Semiconductor pressure sensors were used to assess the transmission time between the initial rises in both the brachial
and tibial artery waves to record the pressure waveform.
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The distance between sampling points of baPWV was
determined based on the height of the subjects. The time
interval between the wave front of the brachial waveform
and the ankle waveform was expressed as the time interval between the brachium and ankle (∆Tba). The final
baPWV was calculated as

baPWV = (La − Lb)/�Tba

(1)

La was the path length from the suprasternal notch to
the ankle, and Lb was the path length from the suprasternal notch to the brachium using the following equations:
La = 0.8129 × height of the participant (in cm) + 12.328

(2)

Lb = 0.2195 × height of the participant (in cm) − 2.0734

(3)
The detailed process has been described in a previous
study [26]. The maximum value of baPWV on the left and
right sides was chosen as the final result of baPWV. The
baPWV was measured at baseline and at the follow-up
visit. The baPWV change was calculated as the baPWV
value at baseline minus the baPWV value at the last visit
during follow-up. The baPWV change rate was calculated as the value of baPWV change divided by the time
distance between baseline and last visit. The slope of
baPWV was defined as the linear regression slope with
examination year as the independent variable and multiple baPWV measurements as the dependent variable.
Statistical analysis

Baseline characteristics are presented as the mean
(standard deviation, SD), median [interquartile range,
IQR] or number (percentage), as appropriate. Differences in baPWV change, baPWV change rate and slope
of baPWV among groups were compared using the
Kruskal–Wallis test.
Multivariate linear regression models were used to estimate the association of the TyG index and TG/HDL-C
ratio with the absolute change, change rate and slope
of baPWV. The TyG index and TG/HDL-C ratio were
both analysed as continuous variables and categorized
into quartiles. To adjust for potential confounding factors, three models were established as follows: model 1
adjusted for age and sex; model 2 adjusted for age, sex,
BMI, smoking status, drinking status, physical activity,
diabetes, dyslipidaemia, baPWV at baseline, and MAP at
baseline and last follow-up; model 3 further adjusted for
FBG (HDL-C if TG/HDL-C ratio analysed), triglyceride,
PBG, LDL-C, eGFR, uric acid, homocysteine, and use of
antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up. The regression coefficient
and its 95% confidence interval (CI) are presented. Spearman’s correlation analyses of the TyG index and TG/

HDL-C ratio with other common cardiometabolic risk
factors were performed. To identify the interaction of
insulin resistance indexes and other variables, the interactive terms were tested in the model.
All of the analyses presented above were conducted
using R software (version 3.6.3). The difference was considered statistically significant at two-sided P < 0.05.

Results
The final analysis included 1,895 individuals. During the
follow-up period, a total of 986 recruited individuals
attended health examinations twice, 612 had three examinations and 297 had four or five examinations. The mean
age of the population was 61.90 ± 12.75 years, and 1,477
(77.9%) were men. At baseline, 1,013 (53.5%) participants were diagnosed with hypertension, and 882 (46.5%)
were diagnosed with prehypertension, among which 335
participants progressed to hypertension at the last visit
of follow-up. The median values of the baPWV change,
the baPWV change rate and the slope of baPWV were
46 cm/s, 9 cm/s/year and 8.11 in the whole population,
respectively, as shown in Table 1. The detailed characteristics according to the quartiles of the TyG index and TG/
HDL-C ratio are presented in Additional file 1: Table S1
and Table S2.
We observed linear and positive associations of the
TyG index and TG/HDL-C ratio with the baPWV
change, baPWV change rate and slope of baPWV, as
shown in Fig. 2. In the fully adjusted model (model 3), a
one-unit increase in the TyG index was associated with
a 149.6 cm/s increase in baPWV change, a 40.4 cm/s/
year increase in the baPWV change rate, and a 34.9 cm/s
increase in the baPWV slope. The average increases of
baPWV change, change rate and slope, comparing participants in the highest quartile versus the lowest of the TyG
index, were 129.5 cm/s (P for trend: < 0.001), 37.6 cm/s/
year (P for trend: < 0.001), and 30.6 (P for trend: 0.002),
respectively. Similarly, a one-unit increase in the TG/
HDL-C ratio was associated with a 37.1 cm/s increase in
baPWV change, a 9.8 cm/s/year increase in the baPWV
change rate, and an 8.0 cm/s increase in the baPWV
slope. The average increases in baPWV change, change
rate and slope, comparing participants in the highest
quartile versus the lowest quartile of the TG/HDL-C
ratio, were 133.4 cm/s (P for trend: 0.002), 43.5 cm/s/
year (P for trend: 0.001), and 33.5 (P for trend: 0.004),
respectively. The detailed regression results are shown
in Tables 2 and 3. The distributions of baPWV change,
baPWV change rate and slope of baPWV among the
quartile groups according to the TyG index are shown
in Fig. 3A–C. The distributions of baPWV parameters
among the quartile groups according to the TG/HDL-C
ratio are shown in Fig. 3D–F. To identify the significant
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Table 1 Characteristics of the study population
Characteristics (N = 1895)
At baseline
Age (years)

61.90 (12.75)

Sex (men, %)

1477 (77.9)

Occupation (n, %)
  Manager

392 (20.7)

  Technician or professional

214 (11.3)

  Worker

187 (9.9)

  Retired

1102 (58.1)

BMI

26.52 (3.22)

Physical activity (n, %)

964 (50.9)

Smoking status: none/former/current 1128 (59.6)/285 (15.0)/482 (25.4)
(n, %)
Current drinking (n, %)

844 (44.5)

SBP (mmHg)

139.64 (12.69)

DBP (mmHg)

78.67 (10.06)

MAP (mmHg)

98.99 (8.60)

Hypertension (n, %)

1013 (53.5)

Antihypertensive medication (n, %)

267 (26.4)

Diabetes (n, %)

323 (17.0)

Dyslipidaemia (n, %)

773 (40.8)

FBG (mmol/L)

5.79 (1.48)

PBG (mmol/L)

7.72 (2.61)

HbA1c (%)

5.94 (0.82)

Triglyceride (mmol/L)

1.86 (1.62)

Total cholesterol (mmol/L)

4.81 (0.98)

LDL-C (mmol/L)

3.11 (0.88)

HDL-C (mmol/L)

1.25 (0.32)

eGFR (mL/min per 1.73 m
 2)

90.88 (26.05)

Uric acid (μmol/L)

365.83 (84.67)

Homocysteine (μmol/L)

12.74 (7.66)

TyG index

1.42 [1.03,1.83]

TG/HDL-C ratio

1.22 [0.78,1.96]

baPWV (cm/s)

1538.00 [1392.00,1769.50]

At last visit of follow up
baPWV (cm/s)

1603.00 [1412.00,1815.50]

Change of baPWV (cm/s)

46.00 [− 251.00,309.50]

Change rate of baPWV (cm/s/year)

9.00 [− 57.22,64.29]

Slope of baPWV

8.11 [− 54.72,66.96]

Hypertension (n, %)

1348 (71.1)

Antihypertensive medication (n, %)

562 (41.7)

Antidiabetic medication (n, %)

151 (8.0)

Lipid-lowering medication (n, %)

273 (14.4)

Data are the mean (SD), median [IQR] or number (%)
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MAP: mean arterial pressure; FBG: fasting blood glucose; PBG:
postprandial blood glucose; HbA1c: glycated haemoglobin; HDL-C: high-density
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; eGFR:
estimated glomerular filtration rate; TyG: triglyceride glucose; baPWV: brachialankle pulse wave velocity
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interaction of the TyG index and TG/HDL-C ratio with
other covariates, such as age, sex, BMI, diabetes, dyslipidaemia, kidney function and life habits, we tested all of
the interaction terms in the fully adjusted model (if not
stratified). We found that only the associations of the
TyG index and TG/HDL-C ratio with baPWV parameters
were significantly different between prehypertensive and
hypertensive populations. The strength of the associations of the TyG index and TG/HDL-C ratio with arterial
stiffness progression were dominant in the hypertensive
population, as shown in Additional file 1: Table S3 and
Fig. 4. In addition, we fitted the joint TyG index and TG/
HDL-C ratio in the fully adjusted model to evaluate the
joint association with artery stiffness progression. There
was a stronger association between the TyG index and
the absolute change, change rate and slope of baPWV
than the TG/HDL-C ratio, as shown in Additional file 1:
Table S4.
The correlation coefficients of the TyG index and TG/
HDL-C ratio with other common cardiometabolic risk
factors are described in Additional file 1: Figure S1. There
were weak correlations of the TyG index and TG/HDL-C
ratio with BMI, SBP, DBP, FBG, PBG, HbA1c, TC, LDLC, serum uric acid, eGFR and homocysteine (Spearman’s
coefficients less than 0.5), apart from TG and HDL-C.

Discussion
In this prospective cohort study, we found that a higher
TyG index and TG/HDL-C ratio were associated with
a higher risk of arterial stiffness progression in the
hypertensive population, during a median follow-up of
4.71 years. The observed associations were still significant after adjusting for important confounding factors,
including age, BMI, blood pressure, medication use, lifestyle habits, serum uric acid, serum homocysteine, eGFR,
diagnosis of diabetes and dyslipidaemia, which are traditional cardiometabolic risk factors and are related to
arterial stiffness progression. TyG index and TG/HDL-C
ratio deserve more attention in clinical practice for preventing artery stiffness and other cerebrocardiovascular
complications in the hypertensive population.
Artery stiffness is a severe adverse event in the hypertensive population. On the other hand, arterial stiffness
can lead to other macro- and microvascular complications and a series of organic damages, such as cerebrovascular diseases and renal damage [3, 27–29]. Moreover,
research has found that some biological factors precede
arterial stiffness progression in patients with hypertension, such as the duration of diabetes mellitus [30] and
sodium sensitivity or resistance [31]. Therefore, identifying early and reliable related factors associated with
artery stiffness in the hypertensive population is of great
importance. The TyG index and TG/HDL-C ratio have
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been reported to be associated with artery stiffness in
the general population in previous studies. However,
evidence in prehypertensive and hypertensive populations is scarce, except for the study by Li et al. [20], which
reported that the TyG index is associated with evaluated
baPWV in a hypertensive population based on a crosssectional design. Our study supplemented the evidence
that the TyG index and TG/HDL-C ratio are associated
with artery stiffness progression for the first time. We
found that a higher TyG index and TG/HDL-C ratio were
associated with an increased baPWV change, baPWV
change rate and slope of baPWV in the hypertensive
population based on a prospective cohort design.
The TyG index and TG/HDL-C ratio, have been of
increasing interest at present. The TyG index and TG/
HDL-C ratio have high sensitivity and specificity for
the diagnosis of insulin resistance compared with the
hyperinsulinaemic-euglycaemic clamp and homeostatic
model assessment in many populations [32, 33]. These
two indicators have a high possibility of being easily
applied in clinical practice for the early detection of IR,
arterial stiffness and other diseases. Previous studies have

also demonstrated the association of the TyG index with
cardiovascular, cerebrovascular and other metabolic diseases. In 2014, Fedchuk et al. [34] measured five steatosis biomarkers, including the TyG index, fatty liver index
(FLI), NAFLD liver fat score (NAFLD-LFS), hepatic steatosis index (HSI) and visceral adiposity index (VAI), and
found that all five steatosis biomarkers could contribute
to the early diagnosis of steatosis and were correlated
with IR. In the Northern Shanghai Study, Zhao et al.
[17] concluded that an elevated TyG index was significantly related to arterial stiffness and nephric microvascular damage, which supported the clinical application
of the TyG index for the assessment of vascular damage. In recent years, several studies have also reported
that the TyG index may predict several cardiovascular
diseases, including acute coronary syndromes, symptomatic CHD and ischaemic stroke [35–39]. For the TG/
HDL-C ratio, in an 8-year Japan Diabetes Complications
Study, Hirohito Sone et al. [40] evaluated conventional
lipid variables, such as TG, non-HDLC, TC/HDL-C
ratio, LDL-C/HDL-C ratio, and TG/HDL-C ratio, for a
relationship with CHD. According to their analyses, all
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Table 2 Association of the TyG index with the absolute change, change rate and slope of baPWV
model 1

model 2

model 3

β

95% CI

P value

β

95% CI

TyG (continuous)

32.034

4.642–59.425

0.022

57.119

22.835–91.402

Quartile 2 (ref: quartile 1)

59.745

10.509–108.982

0.017

61.086

12.582–109.59

Quartile 3

85.613

36.416–134.81

0.001

93.631

43.889–143.373

Quartile 4

74.957

25.494–124.42

0.003

98.555

37.584–159.526

P value

β

95% CI

P value

0.001

149.582

90.823–208.342

< 0.001

0.014

76.297

28.63–123.964

0.002

< 0.001

102.562

52.08–153.044

< 0.001

0.002

129.525

58.723–200.326

Change of baPWV (cm/s)

P for trend

0.002

< 0.001

< 0.001
< 0.001

Change rate of baPWV (cm/s/year)
TyG (continuous)

11.892

3.415–20.368

0.006

17.974

7.307–28.642

0.001

40.372

21.853–58.891

Quartile 2 (ref: quartile 1)

11.870

-3.385–27.125

0.127

12.122

-2.986–27.229

0.116

16.529

1.507–31.551

0.031

Quartile 3

20.615

5.373–35.858

0.008

22.642

7.149–38.135

0.004

24.390

8.481–40.299

0.003

Quartile 4

24.616

9.291–39.941

0.002

30.750

11.76–49.741

0.002

37.607

15.294–59.919

P for trend

0.001

0.001

< 0.001

0.001
< 0.001

Slope of baPWV
TyG (continuous)

9.570

1.538–17.601

0.020

14.238

4.121–24.355

0.006

34.874

17.238–52.51

Quartile 2 (ref: quartile 1)

10.986

-3.469–25.441

0.136

10.888

-3.439–25.215

0.137

14.872

0.57–29.175

0.042

Quartile 3

18.739

4.296–33.182

0.011

20.092

5.399–34.785

0.007

22.163

7.016–37.31

0.004

Quartile 4

20.126

5.604–34.647

0.007

23.648

5.639–41.658

0.010

30.576

9.332–51.82

P for trend

0.004

< 0.001

0.005

0.003

0.002

Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at
baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive
medications at baseline and follow-up

Table 3 Association of TG/HDL-C ratio with the absolute change, change rate and slope of baPWV
Model 1
β

Model 2
95% CI

P value

β

Model 3
95% CI

P value

β

95% CI

P value

Change of baPWV (cm/s)
TG/HDL-C ratio (continuous)
Quartile 2 (ref: quartile 1)

6.795
70.320

− 1.193 to 14.784

21.037–119.604

0.096

4.934

0.005

68.883

− 3.684 to 13.552

19.964–117.802

Quartile 3

83.153

34.299–132.007

0.001

89.453

38.544–140.362

Quartile 4

131.912

82.542–181.282

< 0.001

142.938

78.525–207.35

P for trend

< 0.001

0.062

37.057

7.85–66.264

0.013

0.006

75.317

24.101–126.534

0.004

0.001

84.036

25.516–142.556

0.005

< 0.001

133.420

51.949–214.891

0.001

< 0.001

0.002

Change rate of baPWV (cm/s/year)
TG/HDL-C ratio (continuous)
Quartile 2 (ref: quartile 1)

2.587
14.121

0.115–5.06

0.040

1.880

− 1.149 to 29.392

0.070

13.621

− 0.801 to 4.562

− 1.616 to 28.857

Quartile 3

23.979

8.842–39.117

0.002

25.543

9.687–41.399

Quartile 4

38.237

22.94–53.534

< 0.001

40.369

20.307–60.431

P for trend

< 0.001

0.169

9.768

0.547–18.989

0.038

0.080

19.486

3.325–35.646

0.018

0.002

29.615

11.15–48.08

0.002

< 0.001

43.511

17.804–69.217

0.001

< 0.001

0.001

Slope of baPWV
TG/HDL-C ratio (continuous)
Quartile 2 (ref: quartile 1)

2.253
12.212

− 0.089 to 4.595

− 2.264 to 26.687

Quartile 3

21.636

7.287–35.986

Quartile 4

33.088

18.587–47.589

P for trend

0.060

4.507

0.098

11.300

1.425–6.048

0.045

7.973

0.801–22.317

0.035

− 3.154 to 25.754

0.126

15.465

0.078–30.852

0.049

0.003

21.977

6.935–37.019

0.004

24.296

6.715–41.877

0.007

< 0.001

32.178

13.146–51.21

0.001

33.496

9.02–57.972

0.007

< 0.001

< 0.001

0.004

Model 1: adjusted age and sex; Model 2: age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP
at baseline and follow-up; Model 3: Model 2 plus HDL-C, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or
antihypertensive medications at baseline and follow-up
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Fig. 3 The distributions of the absolute change, change rate and slope of baPWV among the quartile groups according to the TyG index (A–C) and
TG/HDL-C ratio (D–F)

of these variables could predict CHD events in men and
women. Marcello et al. [41] carried out a cross-sectional
study to investigate the association between IR and TG/
HDL-C with CHD and concluded that HOMA-IR and
TG/HDL-C are positively associated with CHD and may
be useful as high-specificity indicators of CHD for risk
stratification. These studies indicate that the TyG index
and TG/HDL-C ratio are promising markers for future
screening of metabolic diseases.
In the current study, we found that the evaluated TyG
index and TG/HDL-C ratio were independently associated with the progression of artery stiffness in the
hypertensive population, while a significant association
was not observed in the prehypertensive population. In
a previous study [42], blood pressure and the hypertensive state itself were reported to worsen the progression
of arterial stiffness. In a review analysis [43], age and
high blood pressure were the two main determinants of
arterial stiffness. The findings in our study imply that
the interaction between hypertensive status and insulin
resistance leads to arterial stiffness progression, which
means that people with hypertension should pay close
attention to insulin resistance indexes to prevent artery

stiffness. Although not completely elucidated, there are
potential mechanisms linking the TyG index and TG/
HDL-C ratio with arterial stiffness. Insulin resistance is
related with endothelial dysfunction, coagulation dysfunction, oxidative stress and inflammation, and cardiac concentric remodeling [44]. Hyperglycemia and
hyperinsulinemia, usually accompanied by hyperlipidemia, are characterized by increased intracellular calcium concentration, increased collagen and advanced
glycation end products, fibrosis and cellular hypertrophy, which reduce arterial elasticity through arterial
remodeling especially in the hypertensive population,
and lead to arterial stiffness [45, 46].
In addition, the TyG index and TG/HDL-C ratio,
derived from fasting glucose, triglycerides and HDLC, showed weak correlations with other components of
metabolic syndrome, which implies that the TyG index
and TG/HDL-C ratio might precede the incidence of
the insulin resistance components [47]. Therefore, the
TyG index and TG/HDL-C ratio may be early biomarkers of insulin resistance and other metabolic diseases,
which warrants further validation in other studies.
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Pre−hypertension Hypertension

Pre−hypertension Hypertension

Fig. 4 Associations of the TyG index and TG/HDL-C ratio with the absolute change, change rate and slope of baPWV in prehypertensive and
hypertensive populations*. *Adjusted for age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at
baseline, FBG (HDL-C if TG/HDL-C ratio analysed), triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, MAP at baseline and follow up, and use of
antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow up

The strengths of the present study include the prospective cohort design to explore the association of the TyG
index and TG/HDL-C ratio with the progression of artery
stiffness in prehypertensive and hypertensive populations, the adjustment of the potential confounding factors, and handling the TyG index and TG/HDL-C ratio
as both continuous variables and categorical variables
to enhance the reliability of our findings. However, the
results should be interpreted in the context of some limitations. First, the sample size was relatively small, and the
95% CI of the estimated effect was wide. In the prehypertensive population, we only observed the evaluated tendency of baPWV change, baPWV change rate and slope
of baPWV without statistical significance. The observed
results in this single-centre study need further validation to generalize the associations in other populations
and to evaluate the underlying biological mechanism
between insulin resistance and artery stiffness progression. Second, the use of antihypertensive medication was
considered in this analysis. However, we failed to collect
the specific types of antihypertensive agents, given that

different antihypertensive medications could have different influences on baPWV measurements. Data on antiplatelet medication were unavailable. Third, we analysed
the association of the TyG index and TG/HDL-C ratio at
baseline with artery stiffness progression in the current
study, and evaluation of the dynamic TyG index and TG/
HDL-C ratio was needed with multiple measurements
and related methods, such as trajectory analysis.

Conclusion
In summary, our findings indicate that the TyG index
and TG/HDL-C ratio are significantly associated with
arterial stiffness progression in hypertensive population,
not in prehypertensive population. Monitoring the TyG
index and TG/HDL-C ratio deserves more attention in
clinical practice for the early prevention of arterial stiffness progression and other vascular complications of
hypertension.
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TyG: Triglyceride glucose index; TG/HDL-C: Triglyceride to high-density lipoprotein cholesterol ratio; baPWV: Brachial-ankle pulse wave velocity; IR: Insulin
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